Natixis Cerevel Therapeutics Holdings, Inc. Transaction History
Natixis
- $16 Billion
- Q4 2024
Shares
2 transactions
Others Institutions Holding CERE
# of Institutions
7Shares Held
5.01MCall Options Held
3.3KPut Options Held
0-
Black Rock Inc. New York, NY3.56MShares$00.0% of portfolio
-
Segantii Capital Management LTD1.14MShares$05.99% of portfolio
-
Tekla Capital Management LLC176KShares$00.22% of portfolio
-
Credit Suisse Ag Zurich, V8112KShares$00.0% of portfolio
-
Kellner Capital, LLC New York, NY20.3KShares$01.55% of portfolio
About Cerevel Therapeutics Holdings, Inc.
- Ticker CERE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 155,752,000
- Description
- Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...